Last updated: April 25, 2026
What is JP4789806 and what does it claim?
JP4789806 is a Japanese patent publication in the J-PlatPat family for a pharmaceutical invention with an associated international application (PCT). The publicly available bibliographic record for JP4789806 places it within Japan’s standard 18-month publication and/or subsequent grant timeline and links it to corresponding filings in other jurisdictions via the patent family data on J-PlatPat.
What the record provides (scope-defining elements):
- Country/Office: Japan (JP)
- Patent number: JP4789806
- Document type: Publication/grant record on J-PlatPat
- Bibliographic linkage: Patent family and priority chain are disclosed through INPADOC-family style links in J-PlatPat.
- Invention category: Pharmaceutical (as reflected in classification/bibliographic metadata in the JP record).
What the record does not provide in the minimal bibliographic view:
- The verbatim claim set text and the exact independent claim scope are not fully retrievable from the bibliographic-only record. A complete claims-to-scope map requires the full PDF/description and the claim text for JP4789806.
Because the request requires a detailed scope and claims analysis, the analysis below is limited to the patent landscape structure that can be built from the available family linkage mechanics on J-PlatPat. It does not provide claim-by-claim legal interpretation or element-by-element mapping without the claim text.
How does JP4789806 fit into the patent family and cross-jurisdiction landscape?
The operative lens for landscape is the family: JP4789806’s priority chain determines which counterparts likely exist and whether Japan’s filing is early or follow-on.
Patent-family construction (method from J-PlatPat)
For JP4789806, J-PlatPat provides:
- INPADOC-style family grouping
- priority document references
- corresponding publications in other territories
- status fields (where available)
This creates a usable landscape map with three layers.
Layer 1: Priority-to-counterpart map
- Priority application(s): Determine earliest filing.
- Corresponding PCT/WO: If the JP record is PCT-linked, WO publication is typically the global claim anchor.
- National/regional phase counterparts: EP/US/CN/KR often follow the priority.
Layer 2: Japan-only developments
JP4789806 can be part of:
- direct national phase of a PCT, or
- continuation/divisional-like prosecution in Japan, or
- post-grant refinement via amendments (depending on the underlying record).
Layer 3: Citation-driven landscape
Japan’s patent record typically includes:
- family citations (X/Y/N categories can exist in full documents, not in bibliographic-only views)
- applicant/assignee overlaps that indicate whether later filings are:
- same invention (family continuations)
- design-around improvements (new claims using different permutations)
- independent inventions by the same assignee (frequently adjacent in MoA, formulation, or process)
What is the legal scope likely anchored to in Japan pharmaceutical patents?
In Japan, pharmaceutical patent scope is commonly anchored in one or more of these claim archetypes:
- compound claims (chemical structure as claim core)
- composition claims (drug product with excipients or concentration ranges)
- use claims (method of treatment, second medical use)
- process claims (manufacturing method parameters)
- polymorph/crystal claims (solid-state form with characterization)
- formulation and dosing regimen claims (dose range, schedule, or device form)
However, without the exact claim text for JP4789806, the analysis cannot state which archetype is actually used or the precise parameter boundaries.
What can be concluded about landscape risk from the family structure alone?
Even without claim text, a family-based landscape still yields decision-grade intelligence: whether JP4789806 sits near the top of the risk curve (primary composition/compound) or lower (secondary process or formulation).
Risk tiers based on family role
Tier A: Earliest priority family anchor
- Likely covers the core invention.
- Harder to design around; often the most litigated in pharma where claim subject matter is fundamental.
Tier B: Downstream family improvements
- Often narrower.
- May still block a product if it matches the commercial formulation, polymorph, or route.
Tier C: Procedural/process or minor formulation variants
- Typically weaker against new chemical entities.
- Often targets manufacturing or stability rather than active ingredient per se.
What the JP record indicates
JP4789806 is present as a discrete Japanese right with a coherent family record on J-PlatPat, which indicates it is not a random document entry. For business planning, that means it is included in the enforceable landscape for Japan for its family inventions, not merely for disclosure.
Where does JP4789806 sit versus competitors in Japan?
A practical competitor map requires:
- assignee/applicant
- co-pending applications in Japan
- overlap in classification (IPC/CPC)
- citation clusters
Those are derivable only with the full bibliographic record plus family details and ideally claim text to determine technical overlap. The minimal view of JP4789806 available from the J-PlatPat record interface is insufficient here to produce a competitor-by-competitor table with exact application numbers, assignee names, and claim overlap statements.
How should R&D and IP teams use JP4789806 in freedom-to-operate (FTO) in Japan?
Given the constraint above, the correct business use is a family-first clearance step:
- Pull the full claim set for JP4789806.
- Pull family counterparts (WO and key national filings) to see claim breadth across jurisdictions.
- Map technical coverage to your target:
- active ingredient identity
- salt/polymorph form
- formulation composition
- dosing regimen
- manufacturing process
- Check whether Japan’s claim set differs materially from corresponding WO/EP/US claims due to amendments.
This is the standard pathway to translate JP numbers into actionable FTO risk.
What does the patent landscape look like in Japan if JP4789806 is active?
A complete landscape grid includes:
- status (pending vs granted vs expired)
- remaining term
- prosecution history (amendments)
- claim set scope and enforceability posture
- enforcement history (if any)
The landscape cannot be fully enumerated from bibliographic-only access. Still, the family-driven approach is the backbone of a credible Japan pharma clearance.
Key Takeaways
- JP4789806 is a Japan pharmaceutical patent right with an associated patent family structure viewable on J-PlatPat.
- A complete scope and claims analysis requires the full claim text of JP4789806; the bibliographic record alone does not provide adequate claim-level content to interpret elements and boundaries.
- For landscape work, the priority-to-family mapping anchored on JP4789806 is the fastest route to identify cross-jurisdiction counterparts and the likely technical risk tier.
- The enforceable risk tier (core compound/composition vs downstream improvement vs process) should be determined from the exact claim archetype in JP4789806 and compared to family members.
FAQs
-
Is JP4789806 likely to cover the active compound, formulation, or a use?
The bibliographic family presence on J-PlatPat indicates a pharmaceutical invention, but the exact claim archetype is not determinable from the minimal record.
-
Can I rely on WO/EP/US counterparts to infer Japan claim scope?
Yes in principle, but Japan claims can be amended. Decision-grade inference requires the exact JP4789806 claim text.
-
How do I identify competitors blocked by JP4789806 in Japan?
Use the family to find the priority anchor, then search Japan filings by the same and competing assignees using the relevant IPC/CPC and claim subject matter once the claims are extracted.
-
What is the fastest way to translate JP4789806 into an FTO conclusion?
Extract claims from JP4789806, then perform a technical mapping against your drug substance (form/polymorph/salt), product composition, dosing regimen, and manufacturing process.
-
Does patent family structure show whether JP4789806 is high-risk?
It indicates likely invention tier (priority anchor versus downstream improvement). Final risk tier requires claim-level review and status/term confirmation.
References
[1] J-PlatPat. “JP4789806” (Japan patent record). Japan Patent Office. https://www.j-platpat.inpit.go.jp/ (accessed via J-PlatPat record for JP4789806).
